Integra Lifesciences (NASDAQ:IART) issued an update on its FY18 earnings guidance on Tuesday morning. The company provided earnings per share (EPS) guidance of $2.25-2.35 for the period, compared to the Thomson Reuters consensus estimate of $2.30. The company issued revenue guidance of $1.46-1.48 billion, compared to the consensus revenue estimate of $1.47 billion.
Shares of Integra Lifesciences (IART) opened at $52.73 on Thursday. The company has a quick ratio of 3.39, a current ratio of 4.49 and a debt-to-equity ratio of 1.26. The company has a market cap of $4,212.67, a P/E ratio of 64.31, a P/E/G ratio of 1.71 and a beta of 0.67. Integra Lifesciences has a 1-year low of $40.51 and a 1-year high of $56.42.
Integra Lifesciences (NASDAQ:IART) last posted its quarterly earnings results on Tuesday, February 27th. The life sciences company reported $0.64 EPS for the quarter, topping analysts’ consensus estimates of $0.56 by $0.08. The company had revenue of $368.60 million for the quarter, compared to analysts’ expectations of $362.64 million. Integra Lifesciences had a net margin of 5.45% and a return on equity of 17.30%. Integra Lifesciences’s revenue was up 44.2% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.52 EPS. analysts expect that Integra Lifesciences will post 2.29 earnings per share for the current fiscal year.
In other news, Director Keith Bradley sold 15,658 shares of the business’s stock in a transaction on Monday, February 26th. The shares were sold at an average price of $55.00, for a total transaction of $861,190.00. Following the completion of the transaction, the director now directly owns 37,074 shares in the company, valued at approximately $2,039,070. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 21.50% of the stock is owned by insiders.
About Integra Lifesciences
Integra LifeSciences Holdings Corporation is a medical technology company. The Company focuses on the development, manufacturing, and marketing of surgical implants and medical instruments. Its segments include Specialty Surgical Solutions, which offers specialty surgical instrumentation for a range of specialties, including product portfolio used in the neurosurgery operating suite and critical care unit, and Orthopedics and Tissue Technologies, which includes differentiated soft tissue repair and tissue regeneration products, and small bone fixation and joint replacement solutions.
Receive News & Ratings for Integra Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.